Term
|
Definition
| statements that are time specific and describe generally what is to be accomplished to address a specific nursing diagnosis |
|
|
Term
|
Definition
| Any preventable adverse drug event involving inappropriate medication use by a patient or health care professional; it may or may not cause the patient harm |
|
|
Term
|
Definition
| An organizational framework for the practice of nursing. Assessment, Nursing Diagnosis, Planning, Implementation, and Evaluation |
|
|
Term
|
Definition
| Descriptions of specific patient behaviors or responses that demonstrate meeting of or achievement of goals related to each nursing diagnosis. These statements are verifiable, framed in behavioral terms, measurable, and time specific. Outcome criteria are considered to be specific whereas goals are broad |
|
|
Term
| Rights of Medication Administration |
|
Definition
| Right dose, right drug, right time, right route, right patient, right documentation, patient right to refuse |
|
|
Term
|
Definition
| Drug interactions in which the effect of a combination of two or more drugs with similar actions is equivalent to the sum of the individual effects of the same drugs given alone. 1+1=2 |
|
|
Term
|
Definition
| Any undesirable occurrence related to administering or failing to administer a prescribed medication |
|
|
Term
|
Definition
| Any unexpected, unintended, undesired, or excessive response to a medication given at therapeutic dosages |
|
|
Term
|
Definition
| A general term for any undesirable effects that are a direct response to one or more drugs |
|
|
Term
|
Definition
| An immunologic hypersensitivity reaction resulting from the unusual sensitivity of a patient to a particular medication; a type of adverse drug event |
|
|
Term
|
Definition
| Drug interactions in which the effect of a combination of two or more drugs is less than the sum of the individual effects of the same drugs given alone 1+1=1 |
|
|
Term
|
Definition
| A measure of the extent of drug absorption for a given drug and route |
|
|
Term
|
Definition
| The barrier system that restricts the passage of various chemicals and microscopic entities between the bloodstream and he CNS |
|
|
Term
|
Definition
| The name that describes the chemical composition and molecular structure of a drug |
|
|
Term
|
Definition
| Any condition, especially one related to a disease state or patient characteristic, including current or recent drug therapy, that renders a particular form of treatment improper or undesirable |
|
|
Term
|
Definition
| A state in which there is a compulsive or chronic need, as for a drug |
|
|
Term
|
Definition
| Any chemical that effects the physiologic processes of a living organism |
|
|
Term
|
Definition
| A method of grouping drugs; may be based on structure or therapeutic use |
|
|
Term
|
Definition
| Alteration in the pharmacologic or pharmacokinetic activity of a given drug caused by the presence of one or more additional drugs; it is usually related to effects on the enzymes required for metabolism of the involved drugs |
|
|
Term
|
Definition
| The length of time the concentration of a drug in the blood or tissues is sufficient to elicit a response |
|
|
Term
|
Definition
| The initial metabolism in the liver of a drug absorbed from the GI tract before the drug reaches systemic circulation through the bloodstream |
|
|
Term
|
Definition
| The name given to a drug by the US Adopted Names Council. Much shorter and simpler than the chemical name and is not protected by trademark |
|
|
Term
|
Definition
| An abnormal and unexpected response to a medication, other than an allergic reaction, that is peculiar to an individual patient |
|
|
Term
|
Definition
| The characteristic that causes two parenteral drugs or solutions to undergo a reaction when mixed or given together that results in the chemical deterioration of at least one of the drugs |
|
|
Term
|
Definition
| Any preventable adverse drug event involving inappropriate medication use by a patient or health care professional; it may or may not cause the patient harm |
|
|
Term
|
Definition
| The time required for a drug to elicit a therapeutic response after dosing |
|
|
Term
|
Definition
| The chemical form of a drug that is administered before it is metabolized by the body’s biochemical reactions into its active or inactive metabolites; a parent drug that is not pharmacologically active itself is called a prodrug. |
|
|
Term
|
Definition
| The time required for a drug to reach its maximum therapeutic effect |
|
|
Term
| Pregnancy Safety Category A |
|
Definition
| Studies indicate no risk to the human fetus |
|
|
Term
| Pregnancy Safety Category B |
|
Definition
| Studies indicate nor risk to the animal fetus; information for humans is not available |
|
|
Term
| Pregnancy Safety Category C |
|
Definition
| Adverse effects reported in the animal fetus; information for humans is not available |
|
|
Term
| Pregnancy Safety Category D |
|
Definition
| Possible fetal risk in humans has been reported; however, in selected cases consideration of the potential benefit versus risk may warrant use of these drugs in pregnant women |
|
|
Term
| Pregnancy Safety Category X |
|
Definition
| Fetal abnormalities have been reported, and positive evidence of fetal risk in humans is available from animal and/or human studies. These drugs are not to be used in pregnant women |
|
|
Term
|
Definition
| Younger than 38 weeks gestation |
|
|
Term
| Neonate or newborn infant |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Controlled Substances Schedule Categories C-I |
|
Definition
o High abuse potential
o No medical use
o Severe physical and psychological dependency potential |
|
|
Term
| Controlled Substances Schedule Categories C-II |
|
Definition
o High abuse potential
o Accepted medical use
o Severe physical and psychological dependency potential |
|
|
Term
| Controlled Substances Schedule Categories C-III |
|
Definition
o Abuse potential less than C-II
o Accepted medical use
o Moderate to low physical and psychological dependency potential |
|
|
Term
| Controlled Substances Schedule Categories C-IV |
|
Definition
o Abuse potential less than C-III
o Accepted medical use
o Limited physical and psychological dependency potential |
|
|
Term
| Controlled Substances Schedule Categories C-V |
|
Definition
o Abuse potential less than C-IV
o Accepted medical use
o Limited physical and psychological dependency potential |
|
|
Term
|
Definition
• 5 mL syringe
• 3 mL syringe
• 1 mL Tuberculin syringe
• Low-dose insulin syringe |
|
|
Term
|
Definition
90 Degrees
Aqueous medications 22- to 27- gauge needle
Viscous medications 18- to 25- gauge needle |
|
|
Term
|
Definition
45 or 90 Degrees
Doses are usually 0.5 – 1.0 mL
25 gauge. ½ to 5/8 inch needle
90 degree for average sized patient
45 degree for thin and/or malnourished patient |
|
|
Term
|
Definition
5-15 Degrees
Dosage usually 0.01 to 0.1 mL
25- to 27-gauge needle 3/8 to 5/8 inch needle |
|
|
Term
|
Definition
Hip
Preferred site for adults and children |
|
|
Term
|
Definition
Upper thigh
Preferred site for immunizations and infants |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Child Eardrop (infants and child younger than 3) |
|
Definition
|
|
Term
|
Definition
| Dozing or drifting off to sleep; can be easily awakened. 2%-5% |
|
|
Term
|
Definition
| Relaxation; can be easily awakened; has occasional REMs and slight eye movement. 50% |
|
|
Term
|
Definition
| Deep sleep; difficult to wake person; respiratory rate, pulse, and BP may decrease. 5% |
|
|
Term
|
Definition
| Very difficult to wake person; person will be groggy if awakened; dreaming occurs; sleepwalking and bedwetting may occur. 10%-15% |
|
|
Term
|
Definition
| REMs occur, vivid dreams occur, breathing may be irregular. 25%-33% |
|
|
Term
|
Definition
| A chemical category of drugs most frequently prescribed as anxiolytic drugs and less frequently as sedative-hypnotic agents. Were the most commonly prescribed sedative-hypnotics, now non-benzodiazepines are more frequently prescribed |
|
|
Term
|
Definition
| A class of drugs that are chemical derivatives of barbituric acid. They are used to induce sedation |
|
|
Term
| 3. Gamma-aminobutyric acid (GABA) |
|
Definition
| The primary inhibitory neurotransmitter found in the brain. A key compound affected by sedative, anxiolytic, psychotropic, and muscle relaxing medications |
|
|
Term
|
Definition
| The maximum concentration of a drug in the body after administration, usually measured in a blood sample for therapeutic monitoring |
|
|
Term
|
Definition
| The science of preparing and dispensing drugs, including dosage form design |
|
|
Term
|
Definition
| The study of the biochemical and physiologic interactions of drugs at their sites of activity |
|
|
Term
|
Definition
| The study of economic factors impacting the cost of drug therapy |
|
|
Term
|
Definition
| The study of the influence of genetic factors on drug response |
|
|
Term
|
Definition
| The study of drugs that are obtained from natural plant and animal sources |
|
|
Term
|
Definition
| The study of what happens to a drug from start to finish |
|
|
Term
|
Definition
| Drug interactions in which the effect of a combination of two or more drugs with similar actions is greater than the sum of individual effects. 1+1=3 |
|
|
Term
|
Definition
| The desired or intended effect of a particular medication |
|
|
Term
|
Definition
| The ratio between the toxic and therapeutic concentrations of a drug |
|
|
Term
|
Definition
| Reduced response to a drug after prolonged use |
|
|
Term
|
Definition
| The condition of producing adverse bodily effects due to poisonous qualities |
|
|
Term
|
Definition
| The commercial name of a drug product by its manufacturer |
|
|
Term
|
Definition
| The lowest concentration of drug reached in the body after it falls from its peak level |
|
|
